FDA Approval of BELBUCA™ (CIII) (Buprenorphine HCl) Buccal Film for Chronic Pain Triggers Milestone Payment of $50 Million to BioDelivery Sciences from Partner Endo Pharmaceuticals

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. SPCX
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to FDA Approval of BELBUCA™ (CIII) (Buprenorphine HCl) Buccal Film for Chronic Pain Triggers Milestone Payment of $50 Million to BioDelivery Sciences from Partner Endo Pharmaceuticals

FBR Affirms BioDelivery Sciences (BDSI) at 'Outperform' Following FDA Approval of BELBUCA

October 26, 2015 9:41 AM EDT

FBR affirms BioDelivery Sciences International, Inc. (NASDAQ: BDSI) with an Outperform rating and $17 price target after the company and Endo International announced that the U.S. Food and Drug Administration (FDA) has approved BELBUCA... More